Skip to main content

Table 1 Reported proportions of categorical change from baseline at month 1 in BCVA in patients with BRVO and CRVO for patients on ranibizumab and sham

From: Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion

 

BRVO

CRVO

Improvement or worsening at month 1

Ranibizumab (n1 = 131)

Sham (n2 = 132)

Relative risk (95% CI)

Ranibizumab (n1 = 130)

Sham (n2 = 130)

Relative risk (95% CI)

Gain ≥ 20 letters

0.191

0.038

5.04 (1.99, 12.76)

0.131

0.031

4.25 (1.47, 12.29)

Gain ≥ 10 letters and <20 letters

0.313

0.197

1.59 (1.04, 2.44)

0.331

0.100

3.31 (1.87, 5.85)

Loss <10 letters and gain <10 letters

0.489

0.705

0.69 (0.56, 0.85)

0.523

0.762

0.69 (0.57, 0.83)

Loss ≥10 letters and <20 letters

0.008

0.045

0.17 (0.02, 1.38)

0.015

0.077

0.20 (0.04, 0.90)

Loss ≥20 letters

0.000

0.015

0.00 (0.00, 0.00)

0.000

0.031

0.00 (0.00, 0.00)

  1. Confidence intervals for relative risk calculated via delta method and reported patient numbers.